New business model for financing pharmaceutical development

This is an interesting development to track. Will this business model really bring returns? Is this a bigger opportunity for university or independent researchers?
GOLDMAN UNVEILS PLANS FOR PHARMA RESEARCH FUNDING
By Andrew JackPublished: December 3 2008 02:00 | Last updated: December 3 2008 02:00
Goldman Sachs is in talks to provide hundreds of millions of dollars of funding to a large pharmaceutical company, in the first evidence of a new business model for the sector that will see financing shifted away from funding companies and towards targeted co-development of specific medicines.
Jon Symonds, managing director at the investment bank in London and former finance director of AstraZeneca, the Anglo-Swedish pharmaceutical group, said a first deal to create a new hybrid model of research and development should be finalised early next year.
This article can be found at:
http://www.ft.com/cms/s/0/e92f9d3c-c0db-11dd-b0a8-000077b07658,_i_email=y.html
"FT" and "Financial Times" are trademarks of The Financial Times.
Copyright The Financial Times Ltd 2008